Molecular markers for lung and colorectal carcinomas

A technology for colorectal cancer and lung cancer, applied in the field of molecular markers

Active Publication Date: 2011-08-17
ADVPHARMA +1
View PDF5 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Thus, there have been some deficiencies and deficiencies in the field to date, particularly with regard to methods for the detection of lung and colorectal cancers in peripheral blood samples

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular markers for lung and colorectal carcinomas
  • Molecular markers for lung and colorectal carcinomas
  • Molecular markers for lung and colorectal carcinomas

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0150] Blood testing steps for molecular markers of lung cancer and colorectal cancer

[0151] Preparation of monocytes. Take peripheral blood (5-8ml) from patients with lung cancer and colorectal cancer, and use BD vacutainer CPT TM Tube (BD, USA), according to its instructions, isolated mononuclear cells (MNC) from normal individuals. The MNC part was added into PBS buffer three times the volume of the whole blood sample, and centrifuged at 2000 rpm for 10 minutes. Then the MNC part was washed with 1 ml of PBS buffer, and centrifuged at 2000 rpm for 5 minutes. Add the final pellet to 2ml of Super RNApure TM reagent (included in SuperRNApure TM kit, Genesis, Taiwan).

[0152] Real-time PCR (Real-time PCR) analysis of cancer marker gene expression. Using Super RNApure TM The kit, according to the instructions, extracts the total RNA from the MNC part. The RNA pellet was dissolved in DEPC-treated water and stored at -80°C until use. Analyze the quality of RNA by 1% ...

Embodiment 2

[0166] Blood tests for molecular markers of lung cancer

[0167] Materials and methods

[0168] Blood samples were taken from lung cancer patients. In this embodiment, 150 lung cancer patients (selected from 3 different hospitals) confirmed by tissue sections were analyzed. Among them, 40 were from National Taiwan University Hospital (Taipei, Taiwan; Region A), 30 were from the General Hospital of the Armed Forces (Taipei, Taiwan; Region A), and 80 were from Taichung Veterans General Hospital (Taichung, Taiwan; Region B) (2006 between April and March 2007). The last group consisted of 28 relapsed lung cancer patients. Table 3 lists all detailed clinicopathological features, including all lung cancer patients (n=150), and new lung cancer patients (n=122). All patients were approved by the Institutional Research Board (IRB) of each hospital.

[0169] table 3

[0170]

[0171] * : NSCLC means non-small cell carcinoma ** : SCLC means small cell carcinoma

[0172] Contr...

Embodiment 3

[0187] Gene signature and prediction of clinical outcome in lung cancer

[0188] The prediction model is established based on the mRNA expression of the gene to be detected, and is used to predict the risk of lung cancer and evaluate the treatment outcome of a specific drug or course of treatment. The equation of the predictive model is a stepwise variable selection method using multiple regression, and the p-value (p-value) is less than 0.1.

[0189] First, the DUSP6 gene was selected using statistical analysis software, and logistic regression was used to form prediction models of N=300 and N=272. The same analysis was performed by including the EIF2S3 gene in the prediction model. Then add other important genes in sequence, and add them in sequence with the aforementioned process until the ideal effective indicators in the case and control study groups of N=300 and N=272 are satisfied, such as sensitivity greater than 80%, specificity greater than 80%, accuracy greater th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Molecular markers for lung and colorectal carcinomas and methods of using them in blood sample assays are disclosed. The method comprises measuring the expression of the markers in a blood sample from a subject for detecting the presence and / or severity of lung and / or colorectal cancer, and for monitoring and / or assessing the prognosis of the subject's response to a cancer therapy. Also disclosed are kits for detecting, diagnosing, and / or monitoring lung or colorectal carcinomas.

Description

[0001] Related application reference [0002] This application claims priority to US Provisional Application No. 61 / 099,008, filed September 22, 2008, which is hereby incorporated by reference in its entirety. technical field [0003] The present invention relates to a tumor-associated molecular marker, in particular to a tumor-associated molecular marker in peripheral blood. Background technique [0004] There are two main types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 80% of lung cancers. The three most common types of non-small cell lung cancer in the United States are lung adenocarcinoma / bronchoalveolar carcinoma (35-40%), squamous cell carcinoma (25-30%), and large cell lung cancer (10-15%). Lung cancer is most likely to be successfully cured if it is diagnosed at an early stage. Early stage cancer is cancer that has not grown to a large size or spread to other parts of the bo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68
CPCC12Q1/6886C12Q2600/158C12Q2600/118
Inventor 滕涵菁李宛真陈瑾妤
Owner ADVPHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap